Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP
- PMID: 12376616
- PMCID: PMC137916
- DOI: 10.1073/pnas.172514599
Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP
Abstract
Parkinson's disease (PD) is most commonly a sporadic illness, and is characterized by degeneration of substantia nigra dopamine (DA) neurons and abnormal cytoplasmic aggregates of alpha-synuclein. Rarely, PD may be caused by missense mutations in alpha-synuclein. MPTP, a neurotoxin that inhibits mitochondrial complex I, is a prototype for an environmental cause of PD because it produces a pattern of DA neurodegeneration that closely resembles the neuropathology of PD. Here we show that alpha-synuclein null mice display striking resistance to MPTP-induced degeneration of DA neurons and DA release, and this resistance appears to result from an inability of the toxin to inhibit complex I. Contrary to predictions from in vitro data, this resistance is not due to abnormalities of the DA transporter, which appears to function normally in alpha-synuclein null mice. Our results suggest that some genetic and environmental factors that increase susceptibility to PD may interact with a common molecular pathway, and represent the first demonstration that normal alpha-synuclein function may be important to DA neuron viability.
Figures





Comment in
-
Etiology of Parkinson's disease: Genetics and environment revisited.Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):13972-4. doi: 10.1073/pnas.242594999. Epub 2002 Oct 21. Proc Natl Acad Sci U S A. 2002. PMID: 12391311 Free PMC article. Review. No abstract available.
Similar articles
-
Mice lacking alpha-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration.Neurotoxicology. 2004 Sep;25(5):761-9. doi: 10.1016/j.neuro.2004.05.002. Neurotoxicology. 2004. PMID: 15288507
-
Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP.J Neurochem. 2000 Feb;74(2):721-9. doi: 10.1046/j.1471-4159.2000.740721.x. J Neurochem. 2000. PMID: 10646524
-
Overexpression of Parkinson's disease-associated alpha-synucleinA53T by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP.J Neurobiol. 2002 Oct;53(1):1-10. doi: 10.1002/neu.10094. J Neurobiol. 2002. PMID: 12360578
-
What have we learnt from CDNA microarray gene expression studies about the role of iron in MPTP induced neurodegeneration and Parkinson's disease?J Neural Transm Suppl. 2003;(65):73-88. doi: 10.1007/978-3-7091-0643-3_5. J Neural Transm Suppl. 2003. PMID: 12946050 Review.
-
alpha-Synuclein- and MPTP-generated rodent models of Parkinson's disease and the study of extracellular striatal dopamine dynamics: a microdialysis approach.CNS Neurol Disord Drug Targets. 2010 Aug;9(4):482-90. doi: 10.2174/187152710791556177. CNS Neurol Disord Drug Targets. 2010. PMID: 20522009 Review.
Cited by
-
Targeted Overexpression of α-Synuclein by rAAV2/1 Vectors Induces Progressive Nigrostriatal Degeneration and Increases Vulnerability to MPTP in Mouse.PLoS One. 2015 Jun 26;10(6):e0131281. doi: 10.1371/journal.pone.0131281. eCollection 2015. PLoS One. 2015. PMID: 26114655 Free PMC article.
-
α-Synuclein oligomers and clinical implications for Parkinson disease.Ann Neurol. 2013 Feb;73(2):155-69. doi: 10.1002/ana.23746. Epub 2012 Dec 7. Ann Neurol. 2013. PMID: 23225525 Free PMC article. Review.
-
Oxidative stress in genetic mouse models of Parkinson's disease.Oxid Med Cell Longev. 2012;2012:624925. doi: 10.1155/2012/624925. Epub 2012 Jul 8. Oxid Med Cell Longev. 2012. PMID: 22829959 Free PMC article. Review.
-
Trichloroethylene and its metabolite TaClo lead to degeneration of substantia nigra dopaminergic neurones: Effects in wild type and human A30P mutant α-synuclein mice.Neurosci Lett. 2019 Oct 15;711:134437. doi: 10.1016/j.neulet.2019.134437. Epub 2019 Aug 15. Neurosci Lett. 2019. PMID: 31422098 Free PMC article.
-
Stereotaxical infusion of rotenone: a reliable rodent model for Parkinson's disease.PLoS One. 2009 Nov 18;4(11):e7878. doi: 10.1371/journal.pone.0007878. PLoS One. 2009. PMID: 19924288 Free PMC article.
References
-
- Scott W. K., Nance, M. A., Watts, R. L., Hubble, J. P., Koller, W. C., Lyons, K., Pahwa, R., Stern, M. B., Colcher, A., Hiner, B. C., et al. (2001) J. Am. Med. Assoc. 286, 2239-2244. - PubMed
-
- Kruger R., Vieira-Saecker, A. M., Kuhn, W., Berg, D., Muller, T., Kuhnl, N., Fuchs, G. A., Storch, A., Hungs, M., Woitalla, D., et al. (1999) Ann. Neurol. 45, 611-617. - PubMed
-
- Polymeropoulos M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) Science 276, 2045-2047. - PubMed
-
- Kruger R., Kuhn, W., Muller, T., Woitalla, D., Graeber, M., Kosel, S., Przuntek, H., Epplen, J. T., Schols, L. & Riess, O. (1998) Nat. Genet. 18, 106-108. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous